结直肠癌组织中SNAT3表达水平与临床病理生物学的关系
Expression of SNAT3 in Colorectal Cancer Tissues and Its Relationship with Clinicopathological Biological Features
DOI: 10.12677/WJCR.2018.84023, PDF,  被引量   
作者: 何 宇, 余育俊, 黄瀚章, 王 琛, 黄国裕, 韩少良*:温州医科大学附属第一医院胃肠外科,浙江 温州
关键词: 结直肠肿瘤SNAT3基因转移预后Colorectal Neoplasm SNAT3 Gene Metastasis Prognosis
摘要: 目的:探讨钠耦合中性氨基酸转运蛋白A3 (SNAT3)在结直肠癌组织中的表达及其临床意义。方法:采用免疫组化检测96例结直肠癌组织中SNAT3蛋白的表达情况,分析其与结直肠癌患者临床病理指标之间的关系。结果:本组结直肠癌SNAT3蛋白高表达率为56.3% (54/96例),其中癌浸润深度T3 + T4病例的SNAT3蛋白表达率(74.1%、40/57例)显著高于T1 + T2病例(25.9%、14/39例) (P < 0.05);低分化型癌SNAT3蛋白表达率(88.9%、16/18例)显著高于分化型癌(48.7%、38/78例) (P < 0.05),淋巴结转移病例SNAT3表达水平(64.8%、35/48例)显著高于无淋巴结转移(35.2%、19/48例) (P < 0.05);与I + II期患者相比,III +IV患者的SNAT3蛋白表达率显著升高(75.9%、41/58例vs. 24.1%、13/38例) (P < 0.01);且复发转移结直肠癌的SNAT3表达率(81.8%、18/22例)显著高于无转移患者(48.6%、36/74例) (P < 0.01)。本组除3例失访外,其余93例随访资料完整,1、3、5年生存率分别为89.2% (83/93例)、38.7% (36/93例)及30.1% (28/93例),且SNAT3阳性患者的1、3、5年生存率显著低于阴性病例(86.5% vs. 92.7%、32.7% vs. 46.3%及25.0% vs. 36.6%) (P < 0.05)。结论:SNAT3蛋白在结直肠癌组织中高表达,其高表达可能与结直肠癌的侵袭和转移密切相关,且可能在结直肠癌转移中发挥重要作用。
Abstract: Objective: To investigate the expression of Na + coupled neutral amino acid protein A3 (SNAT3) protein in colorectal cancer tissues and its clinical significance. Methods: The expression of SNAT3 protein in 96 cases of colorectal cancer was detected by immunohistochemical staining, and the relationship between clinicopathological characteristics and colorectal cancer was analyzed. Results: The over-expression rate of SNAT3 protein in colorectal cancer was 56.3% (54/96 cases), including the over-expression rate of SNAT3 in depth of T3 + T4 patients was 74.1% (40/57 cases) was significantly higher that (25.9%, 14/39 cases) in T1 + T2 patients (P < 0.05), over-expression rate of SNAT3 (88.9%, 16/18 cases) in poorly-differentiated cancer patients was significantly higher than that (48.7%, 38/78 cases) in well-differentiated cancer patients (P < 0.05), over-expression rate of SNAT3 (64.8%, 35/48 cases) in patients with lymph node involvement was significantly higher than that (35.2%, 19/48 cases) in patients without (P < 0.05). Compared with I + II patients, the expression rate of SNAT3 protein in patients with stage III + IV increased significantly (75.9%, 41/58 cases vs. 24.1%, 13/38 cases, P < 0.01). Moreover, the expression rate of SNAT3 protein (81.8%, 18/22 cases) in patients with stage recurrence and metastasis was significantly higher that (48.6%, 36/74cases) P < 0.01). In this group, 93 patients had complete followed up data except 3 missing cases, the 1, 3, 5-year survival rate were 89.2% (83/93 cases), 38.7% (36/93 cases) and The 1, 3, 5 survival rate of SNAT3 positive patients was significantly lower than that of negative cases (86.5% vs. 92.7%, 32.7% vs. 46.3% and 25.0% vs. 36.6%) (P < 0.05). Conclusions: SNAT3 protein was highly expressed in colorectal cancer tissues, and its high expression may be closely related to invasion and metastasis of colorectal cancer, and may play an important role in the metastasis of colorectal cancer.
文章引用:何宇, 余育俊, 黄瀚章, 王琛, 黄国裕, 韩少良. 结直肠癌组织中SNAT3表达水平与临床病理生物学的关系[J]. 世界肿瘤研究, 2018, 8(4): 144-149. https://doi.org/10.12677/WJCR.2018.84023

参考文献

[1] Yang, K., Yan, J., Peng, L., et al. (2016) Effect of PLCε Gene Silencing on Inhibiting the Cancerous Transformation of Ulcerative Colitis. Experimental and Therapeutic Medicine, 12, 422-426.
[Google Scholar] [CrossRef] [PubMed]
[2] Wang, Y., Fu, L., Cui, M., et al. (2017) Amino Acid Transporter SLC38A3 Promotes Metastasis of Non-Small Cell LUNG Cancer Cells by Activating PDK1. Cancer Letters, 393, 8-15.
[Google Scholar] [CrossRef] [PubMed]
[3] Rubioaliaga I, Wagner C A. Regulation and function of the SLC38A3/SNAT3 glutamine transporter. Channels. 1933, 10(6):440.
[Google Scholar] [CrossRef] [PubMed]
[4] Wang, K., Cao, F., Fang, W., et al. (2013) Activation of SNAT1/SLC38A1 in Human Breast Cancer: Correlation with p-Akt Overexpression. BMC Cancer, 13, 343.
[Google Scholar] [CrossRef] [PubMed]
[5] Yu, W.L., Cong, W.M., Zhang, Y., et al. (2011) Overexpression of ATA1/SLC38A1 Predicts Future Recurrence and Death in Chinese Patients with Hilar Cholangiocarcinoma. Journal of Surgical Research, 171, 663-668.
[Google Scholar] [CrossRef] [PubMed]
[6] Sidoryk, M., Matyja, E., Dybel, A., et al. (2004) Increased Expression of a Glu-tamine Transporter SNAT3 Is a Marker of Malignant Gliomas. NeuroReport, 15, 575-578.
[Google Scholar] [CrossRef] [PubMed]
[7] Bertero, L., Massa, F., Metovic, J., et al. (2018) Eighth Edition of the UICC Classification of Malignant Tumors: An Overview of the Changes in the Pathological TNM Classification Criteria-What Has Changed and Why? Virchows Arch., 472, 519-531.
[8] Jenstad, M. and Chaudhry, F.A. (2013) The Amino Acid Transporters of the Glutamate/GABA-Glutamine Cycle and Their Impact on Insulin and Glucagon Secretion. Frontiers in Endocrinology, 4, 199.
[Google Scholar] [CrossRef] [PubMed]
[9] Bürki, R., Mohebbi, N., Bettoni, C., et al. (2015) Impaired Expression of Key Molecules of Ammoniagenesis Underlies Renal Acidosis in a Rat Model of Chronic Kidney Disease. Nephrology Dialysis Trans-plantation, 30, 770-781.
[Google Scholar] [CrossRef] [PubMed]
[10] Mackenzie, B. and Erickson, J.D. (2004) Sodium-Coupled Neutral Amino Acid (System N/A) Transporters of the SLC38 Gene Family. Pflügers Archiv, 447, 784-795.
[Google Scholar] [CrossRef] [PubMed]
[11] Kondoh, N., Imazeki, N., Arai, M., et al. (2007) Activation of a System A Amino Acid Transporter, ATA1/SLC38A1, in Human Hepatocellular Carcinoma and Preneoplastic Liver Tissues. International Journal of Oncology, 31, 81-87.
[12] 王新军, 杨卓, 杨如意, 袁小威, 孙利坤, 牛晓. 脑胶质瘤组织SNAT1蛋白表达及其意义[J]. 中国神经精神疾病杂志, 2016, 42(7): 426-430.